Elsevier

The Lancet

Volume 364, Issue 9447, 13–19 November 2004, Pages 1731-1732
The Lancet

Comment
Vaccination against human papillomaviruses shows great promise

https://doi.org/10.1016/S0140-6736(04)17410-2Get rights and content

References (11)

  • H zur Hausen

    Human papillomaviruses and cancer

    Bibl Haemotol

    (1975)
  • M Durst et al.

    A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions

    Proc Natl Acad Sci USA

    (1983)
  • M Lehtinen et al.

    Serological diagnosis of human papillomavirus type 16 infection and the risk for subsequent development of cervical carcinoma

    BMJ

    (1996)
  • N Munoz et al.

    Epidemiological classification of human papillomavirus types associated with cervical cancer

    N Engl J Med

    (2003)
  • CD Harro et al.

    Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like-particle vaccine

    J Natl Cancer Inst

    (2001)
There are more references available in the full text version of this article.

Cited by (40)

  • HPV cervical infections and serological status in vaccinated and unvaccinated women

    2020, Vaccine
    Citation Excerpt :

    Second, as with any public health interventions against infectious diseases, it can be jeopardised by microbial diversity. In the case of HPVs, it has been argued that certain genotypes could indirectly benefit from the niches vacated following vaccination [5,6]. Most infections by HPVs occur in young adults.

  • Vaccination and the evolutionary ecology of human papillomavirus

    2008, Vaccine
    Citation Excerpt :

    The two low-risk types 6 and 11 cause greater than 90% of genital wart cases. Vaccination against HPV thus offers the promise of reducing the global burden of cervical cancer and other HPV-related diseases [5,6]. HPV transmission is quite effective, occurring in an estimated 60% of sexual partnerships [7].

  • Review of current knowledge on HPV vaccination: An Appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

    2007, Journal of Clinical Virology
    Citation Excerpt :

    Type-specific persistence, defined as presence of the same HPV type at two or more consecutive visits separated by 6–12 months, is another interesting outcome measure (Lowy and Frazer, 2003). Comparing the incidence of cervical and other HPV-associated cancers in vaccinated and non-vaccinated cohorts, by linkage to cancer registries, will provide the ultimate proof of protection against cancer (Lehtinen, 2004, 2005; Lehtinen et al., 2006a,b). In anticipation of such results, estimations of the impact of HPV vaccination on the burden of cervical cancer incidence and mortality must be based on the observed surrogate endpoints using mathematical modelling (Barnabas et al., 2006; Garnett et al., 2006).

View all citing articles on Scopus
View full text